Does the media refer more to DCTH or ESTA?

In the previous week, Establishment Labs had 5 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Establishment Labs and 3 mentions for Delcath Systems. Establishment Labs' average media sentiment score of 1.48 beat Delcath Systems' score of 0.98 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVCR or DCTH more profitable?

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Delcath Systems 0.56% 0.46% 0.42%

Does the media favor NVCR or DCTH?

In the previous week, NovoCure had 2 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for NovoCure and 3 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.98 beat NovoCure's score of 0.48 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DCTH or LMAT?

In the previous week, LeMaitre Vascular had 8 more articles in the media than Delcath Systems. MarketBeat recorded 11 mentions for LeMaitre Vascular and 3 mentions for Delcath Systems. LeMaitre Vascular's average media sentiment score of 1.12 beat Delcath Systems' score of 0.98 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to DCTH or INSP?

In the previous week, Inspire Medical Systems had 5 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Inspire Medical Systems and 3 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.66 beat Delcath Systems' score of 0.98 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to DCTH or KMTS?

In the previous week, Delcath Systems and Delcath Systems both had 3 articles in the media. Delcath Systems' average media sentiment score of 0.98 beat Kestra Medical Technologies' score of 0.62 indicating that Delcath Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Delcath Systems (DCTH) Competitors

$16.34 -0.05 (-0.31%)

As of 08/28/2026 04:00 PM Eastern

Compare

DCTH vs. ESTA, NVCR, LMAT, INSP, and KMTS

Should you buy Delcath Systems stock or one of its competitors? Delcath Systems's main competitors and comparable companies include Establishment Labs (ESTA), NovoCure (NVCR), LeMaitre Vascular (LMAT), Inspire Medical Systems (INSP), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Delcath Systems compare to Establishment Labs?

Delcath Systems (NASDAQ:DCTH) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Delcath Systems has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.65	$2.70M	$0.01	1,634.00
Establishment Labs	$211.08M	9.97	-$51.06M	-$1.31	N/A

Delcath Systems has a net margin of 0.56% compared to Establishment Labs' net margin of -15.82%. Delcath Systems' return on equity of 0.46% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Establishment Labs	-15.82%	-196.69%	-10.73%

Delcath Systems has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Delcath Systems presently has a consensus price target of $23.17, indicating a potential upside of 41.78%. Establishment Labs has a consensus price target of $100.25, indicating a potential upside of 41.92%. Given Establishment Labs' higher possible upside, analysts plainly believe Establishment Labs is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Establishment Labs had 5 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Establishment Labs and 3 mentions for Delcath Systems. Establishment Labs' average media sentiment score of 1.48 beat Delcath Systems' score of 0.98 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Delcath Systems beats Establishment Labs on 9 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Delcath Systems has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.17	-$136.23M	-$1.30	N/A
Delcath Systems	$85.23M	6.65	$2.70M	$0.01	1,634.00

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Delcath Systems	0.56%	0.46%	0.42%

In the previous week, NovoCure had 2 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for NovoCure and 3 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.98 beat NovoCure's score of 0.48 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.6% of NovoCure shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NovoCure has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

NovoCure presently has a consensus target price of $21.20, indicating a potential upside of 18.97%. Delcath Systems has a consensus target price of $23.17, indicating a potential upside of 41.78%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Delcath Systems beats NovoCure on 13 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to LeMaitre Vascular?

Delcath Systems (NASDAQ:DCTH) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, LeMaitre Vascular had 8 more articles in the media than Delcath Systems. MarketBeat recorded 11 mentions for LeMaitre Vascular and 3 mentions for Delcath Systems. LeMaitre Vascular's average media sentiment score of 1.12 beat Delcath Systems' score of 0.98 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

LeMaitre Vascular has higher revenue and earnings than Delcath Systems. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.65	$2.70M	$0.01	1,634.00
LeMaitre Vascular	$249.60M	7.37	$57.73M	$2.85	28.23

Delcath Systems presently has a consensus price target of $23.17, indicating a potential upside of 41.78%. LeMaitre Vascular has a consensus price target of $110.60, indicating a potential upside of 37.48%. Given Delcath Systems' stronger consensus rating and higher probable upside, research analysts clearly believe Delcath Systems is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Delcath Systems has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to Delcath Systems' net margin of 0.56%. LeMaitre Vascular's return on equity of 15.63% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
LeMaitre Vascular	25.02%	15.63%	10.06%

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

LeMaitre Vascular beats Delcath Systems on 11 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Inspire Medical Systems?

Delcath Systems (NASDAQ:DCTH) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Inspire Medical Systems had 5 more articles in the media than Delcath Systems. MarketBeat recorded 8 mentions for Inspire Medical Systems and 3 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.66 beat Delcath Systems' score of 0.98 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Inspire Medical Systems has higher revenue and earnings than Delcath Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.65	$2.70M	$0.01	1,634.00
Inspire Medical Systems	$911.98M	1.95	$145.42M	$4.62	13.31

Delcath Systems currently has a consensus target price of $23.17, indicating a potential upside of 41.78%. Inspire Medical Systems has a consensus target price of $66.19, indicating a potential upside of 7.64%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts plainly believe Delcath Systems is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21

Delcath Systems has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Inspire Medical Systems has a net margin of 15.03% compared to Delcath Systems' net margin of 0.56%. Inspire Medical Systems' return on equity of 8.64% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Inspire Medical Systems	15.03%	8.64%	7.45%

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Inspire Medical Systems beats Delcath Systems on 11 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Delcath Systems (NASDAQ:DCTH) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Delcath Systems presently has a consensus price target of $23.17, suggesting a potential upside of 41.78%. Kestra Medical Technologies has a consensus price target of $28.14, suggesting a potential upside of 9.76%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Delcath Systems has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Delcath Systems has higher earnings, but lower revenue than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.65	$2.70M	$0.01	1,634.00
Kestra Medical Technologies	$95.13M	15.79	-$131.61M	-$2.42	N/A

Delcath Systems has a net margin of 0.56% compared to Kestra Medical Technologies' net margin of -138.35%. Delcath Systems' return on equity of 0.46% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Delcath Systems and Delcath Systems both had 3 articles in the media. Delcath Systems' average media sentiment score of 0.98 beat Kestra Medical Technologies' score of 0.62 indicating that Delcath Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$566.98M	$5.88B	$7.21B	$12.91B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	1,635.64	25.92	273.16	25.42
Price / Sales	6.65	68.64	625.99	92.72
Price / Cash	312.58	33.03	76.74	53.00
Price / Book	4.68	6.18	12.98	6.14
Net Income	$2.70M	$149.01M	$3.48B	$348.86M
7 Day Performance	-4.67%	-0.24%	0.13%	-0.80%
1 Month Performance	41.11%	7.85%	8.37%	5.56%
1 Year Performance	48.28%	6.22%	24.55%	15.57%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	3.7821 of 5 stars	$16.34 -0.3%	$23.17 +41.8%	+50.2%	$566.98M	$85.23M	1,635.64	60	News Coverage
ESTA Establishment Labs	3.9581 of 5 stars	$72.40 +0.5%	$100.25 +38.5%	+72.3%	$2.16B	$211.08M	N/A	1,004	News Coverage Positive News
NVCR NovoCure	2.5792 of 5 stars	$17.56 +4.8%	$21.20 +20.7%	+48.3%	$2.04B	$655.35M	N/A	1,605	News Coverage Positive News Analyst Downgrade
LMAT LeMaitre Vascular	4.8505 of 5 stars	$79.45 -0.6%	$110.60 +39.2%	-15.6%	$1.82B	$262.43M	27.92	490	Positive News
INSP Inspire Medical Systems	3.2234 of 5 stars	$61.11 -0.6%	$66.19 +8.3%	-32.7%	$1.77B	$911.98M	13.23	1,333	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. ESTA, NVCR, LMAT, INSP, and KMTS

How does Delcath Systems compare to Establishment Labs?

Summary

How does Delcath Systems compare to NovoCure?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Summary

How does Delcath Systems compare to Inspire Medical Systems?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. ESTA, NVCR, LMAT, INSP, and KMTS

How does Delcath Systems compare to Establishment Labs?

Which has better valuation & earnings, DCTH or ESTA?

Is DCTH or ESTA more profitable?

Which has more risk and volatility, DCTH or ESTA?

Do insiders & institutionals believe in DCTH or ESTA?

Do analysts prefer DCTH or ESTA?

Does the media refer more to DCTH or ESTA?

Summary

How does Delcath Systems compare to NovoCure?

Which has better valuation & earnings, NVCR or DCTH?

Is NVCR or DCTH more profitable?

Does the media favor NVCR or DCTH?

Do institutionals & insiders believe in NVCR or DCTH?

Which has more volatility and risk, NVCR or DCTH?

Do analysts rate NVCR or DCTH?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Does the media prefer DCTH or LMAT?

Which has better earnings and valuation, DCTH or LMAT?

Do analysts rate DCTH or LMAT?

Which has more volatility & risk, DCTH or LMAT?

Is DCTH or LMAT more profitable?

Do institutionals and insiders hold more shares of DCTH or LMAT?

Summary

How does Delcath Systems compare to Inspire Medical Systems?

Does the media refer more to DCTH or INSP?

Which has stronger earnings and valuation, DCTH or INSP?

Do analysts prefer DCTH or INSP?

Which has more risk & volatility, DCTH or INSP?

Is DCTH or INSP more profitable?

Do insiders and institutionals have more ownership in DCTH or INSP?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Do analysts recommend DCTH or KMTS?

Which has more risk and volatility, DCTH or KMTS?

Which has higher earnings & valuation, DCTH or KMTS?

Is DCTH or KMTS more profitable?

Do insiders and institutionals hold more shares of DCTH or KMTS?

Does the media refer more to DCTH or KMTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools